DAB2IP Antibody, HRP conjugated

說明書

中文名稱：

DAB2IP兔多克隆抗體, HRP偶聯
貨號：

CSB-PA730138OB01HU
規格：

￥880
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) DAB2IP Polyclonal antibody
Uniprot No.：

Q5VWQ8
基因名：

DAB2IP
別名：

DAB2IP antibody; AF9Q34 antibody; AIP1 antibody; KIAA1743Disabled homolog 2-interacting protein antibody; DAB2 interaction protein antibody; DAB2-interacting protein antibody; ASK-interacting protein 1 antibody; AIP-1 antibody; DOC-2/DAB-2 interactive protein antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Peptide sequence from Human Disabled homolog 2-interacting protein (85-100AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

HRP
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Functions as a scaffold protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Involved in several processes such as innate immune response, inflammation and cell growth inhibition, apoptosis, cell survival, angiogenesis, cell migration and maturation. Plays also a role in cell cycle checkpoint control; reduces G1 phase cyclin levels resulting in G0/G1 cell cycle arrest. Mediates signal transduction by receptor-mediated inflammatory signals, such as the tumor necrosis factor (TNF), interferon (IFN) or lipopolysaccharide (LPS). Modulates the balance between phosphatidylinositol 3-kinase (PI3K)-AKT-mediated cell survival and apoptosis stimulated kinase (MAP3K5)-JNK signaling pathways; sequesters both AKT1 and MAP3K5 and counterbalances the activity of each kinase by modulating their phosphorylation status in response to proinflammatory stimuli. Acts as a regulator of the endoplasmic reticulum (ER) unfolded protein response (UPR) pathway; specifically involved in transduction of the ER stress-response to the JNK cascade through ERN1. Mediates TNF-alpha-induced apoptosis activation by facilitating dissociation of inhibitor 14-3-3 from MAP3K5; recruits the PP2A phosphatase complex which dephosphorylates MAP3K5 on 'Ser-966', leading to the dissociation of 13-3-3 proteins and activation of the MAP3K5-JNK signaling pathway in endothelial cells. Mediates also TNF/TRAF2-induced MAP3K5-JNK activation, while it inhibits CHUK-NF-kappa-B signaling. Acts a negative regulator in the IFN-gamma-mediated JAK-STAT signaling cascade by inhibiting smooth muscle cell (VSMCs) proliferation and intimal expansion, and thus, prevents graft arteriosclerosis (GA). Acts as a GTPase-activating protein (GAP) for the ADP ribosylation factor 6 (ARF6) and Ras. Promotes hydrolysis of the ARF6-bound GTP and thus, negatively regulates phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent TLR4-TIRAP-MyD88 and NF-kappa-B signaling pathways in endothelial cells in response to lipopolysaccharides (LPS). Binds specifically to phosphatidylinositol 4-phosphate (PtdIns4P) and phosphatidylinositol 3-phosphate (PtdIns3P). In response to vascular endothelial growth factor (VEGFA), acts as a negative regulator of the VEGFR2-PI3K-mediated angiogenic signaling pathway by inhibiting endothelial cell migration and tube formation. In the developing brain, promotes both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex in a glial-dependent locomotion process. Probable downstream effector of the Reelin signaling pathway; promotes Purkinje cell (PC) dendrites development and formation of cerebellar synapses. Functions also as a tumor suppressor protein in prostate cancer progression; prevents cell proliferation and epithelial-to-mesenchymal transition (EMT) through activation of the glycogen synthase kinase-3 beta (GSK3B)-induced beta-catenin and inhibition of PI3K-AKT and Ras-MAPK survival downstream signaling cascades, respectively.
基因功能參考文獻：
1. Our study shows that DAB2IP harbored frameshift mutations and intratumoral heterogeneity as well as expression loss in gastric and colorectal cancers PMID: 30477644
2. The results indicated significant down-regulation of DAB2IP transcript variant 1 in prostatic cancerous tissues compared to paired normal tissues PMID: 30301636
3. The role of miR-367 in the pathogenesis of osteosarcoma via DAB2IP expression is reported. PMID: 28837878
4. mutp53 augments insulin-induced AKT1 activation by binding and inhibiting the tumor suppressor DAB2IP (DAB2-interacting protein) in the cytoplasm PMID: 28667123
5. variants DAB2IP-rs7025486[A] and SORT1-rs599839[G] are associated with abdominal aortic aneurysm expansion. PMID: 28698188
6. Low expression of DAB2IP is associated with nasopharyngeal carcinoma. PMID: 28586035
7. These findings suggest that DAB2IP is a direct target of miRNA-556-3p, and endogenous miRNA-556-3p expression shows inverse correlation with simultaneous DAB2IP expression in bladder cancer (BC)tissues and cells. miRNA-556-3p functions as a tumor promoter in tumorigenesis and metastasis of BC by targeting DAB2IP PMID: 28440444
8. Low DAB2IP expression is associated with neoplasms. PMID: 27036023
9. Results identified PRRT2 and DAB2IP to be frequently mutated in all different cancer cell line types. Further analysis showed that both genes were also frequently mutated in colorectal and endometrial cancer patient samples. PMID: 27907910
10. Data suggest that DAB2IP CpG1 methylation is a practical and repeatable biomarker for renal cell carcinoma (ccRCC), which can provide prognostic value that complements the current staging system. PMID: 27129174
11. PROX1 overexpression in DAB2IP-deficient prostate cancer cells could enhance the accumulation of HIF1alpha protein by inhibiting ubiquitin pathway and then consequently induce an epithelial-mesenchymal transition response. PMID: 27476001
12. Study shows that up to 62% of luminal B cancers have lost expression of at least one of the DAB2IP and RASAL2 genes. However, the tumors that have lost both genes frequently present as advanced disease and are more likely to recur. Importantly, the report provide evidence that DAB2IP and RASAL2 can individually function as tumor suppressors in breast cancer. PMID: 27974415
13. The low expression of DAB2IP in bladder carcinoma cells was related to drug resistance. PMID: 28502307
14. Down-regulation of DAB2IP correlated negatively with hnRNPK and MMP2 expressions in CRC tissues. In conclusion, our study elucidates a novel mechanism of the DAB2IP/hnRNPK/MMP2 axis in the regulation of CRC invasion and metastasis, which may be a potential therapeutic target. PMID: 28335083
15. DAB2IP appears to be a new prognostic/predictive marker for metastatic renal cell cancer (mRCC) patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC. PMID: 26876207
16. Along with the reduction of ovarian cancer-2/disabled homolog 2 (DOC-2/DAB2) interactive protein (DAB2IP) expression, EGR-1 gene was upregulated in FI-treated cells. On the other hand, downregulation of EGR-1 gene expression sensitized radioresistant cells to IR accompanied by DAB2IP overexpression and STAT3 inactivation. In addition, NF-kappaB inhibitor, BAY11-7082 enhanced resistant cells' radiosensitivity and chemos... PMID: 27834104
17. Our findings demonstrate a novel function of DAB2IP in the maintenance of KT-MT structure and SAC regulation during mitosis which is essential for chromosomal stability. PMID: 27568005
18. DAB2IP may be involved in forming acquired radioresistance in PC3 cells. DAB2IP-deficient cells are resistant to low and high-LET radiation using different mechanisms. DAB2IP-deficient cells are resistant to both gamma-rays and alpha-particles. PMID: 27177018
19. our data provided evidence to verify that miR-92b was able to directly target DAB2IP, a well-known tumor suppressor, and inhibit epithelialmesenchymal transition of bladder cancer cells PMID: 27430302
20. DAB2IP protein levels are higher in bladder cancer than in upper tract urothelial carcinoma and in superficial bladder cancer PMID: 27003158
21. Infiltrating T cells regulate ERbeta/DAB2IP signals in renal cell carcinoma. PMID: 26587829
22. Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy PMID: 26471467
23. Data show that colorectal cancer (CRC) patients with lower DAB2 interaction protein (DAB2IP) expression had shorter overall survival time. PMID: 26564738
24. strongly expressed in villi and extravillous trophoblasts but not in pre-eclampsia placentas PMID: 25604087
25. DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance. PMID: 26410305
26. Snail and DAB2IP interact to regulate EMT, invasion and metastasis in colorectal cancer PMID: 26336990
27. High glucose increases AIP1 expression and decreases the expression of HIF-1alpha and downstream molecules. Decreased HIF-1alpha signaling may be regulated by increased AIP1 under high glucose. PMID: 26021979
28. Immunohistochemical study exhibited an inverse correlation between DAB2IP and Skp2 protein expression in the prostate cancer tissue microarray. PMID: 25115390
29. An inverse correlation between CD117 or ZEB1 and DAB2IP is also found in clinical specimens. PMID: 25043300
30. miR-889 is an important regulator in ESCC and both miR-889 and DAB2IP may serve as promising biomarkers and therapeutic targets in patients with ESCC. PMID: 25841337
31. Study showed that DAB2IP can be functionally inactivated by physical interaction with mutant p53 proteins with implications for the response of cancer cells to inflammatory cytokines. PMID: 25454946
32. our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development PMID: 24912918
33. downregulation of DAB2IP is associated with features of biologically aggressive urothelial carcinoma of the bladder and results in cell proliferation, migration, and invasion of bladder cancer. PMID: 24684735
34. This study unveils a new regulation of the Egr-1/Clusterin signaling network by DAB2IP. Loss of DAB2IP expression in CRPC cells signifies their chemoresistance PMID: 23838317
35. DAB2IP is a unique intrinsic androgen receptor modulator in normal cells, and likely can be further developed into a therapeutic agent for rpostate cancer. PMID: 23604126
36. Human lymphatic endothelial cells with AIP1 small interfering RNA knockdown show attenuated VEGF-C-induced VEGFR-3 signaling. PMID: 24407031
37. DAB2IP expression was reduced in patients with pancreatic cancer compared with those with no cancer. DAB2IP expression was correlated with the KRAS gene, perineurial invasion and clinical stage of the disease. PMID: 23558076
38. In this study, we show a novel function of DAB2IP in suppressing radiation-induced and DNA-PKcs-associated autophagy and promoting apoptosis in prostate cancer cells. PMID: 23308052
39. Our results for the first time provided new insight into susceptibility factors of hDAB2IP gene variants in carcinogenesis of gastric cancer. PMID: 23246699
40. Studies indicate that DAB2IP and EZH2 are inversely expressed in medulloblastoma. PMID: 22696229
41. Both internalization and ASK1-interacting protein-1 association are required for TNFR2-dependent JNK and apoptotic signaling in endothelial cells. PMID: 22743059
42. Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. PMID: 22168621
43. A sequence variant in DAB2IP on chromosome 9 is associated with coronary heart disease PMID: 21444365
44. the 97906A variant genotypes are associated with the increased risk and early onset of lung cancer, particularly in males. PMID: 22046421
45. PP2A and DAB2IP cooperatively induce activation of ASK1-JNK signaling and vascular endothelial cell apoptosis. PMID: 18292600
46. the A allele of rs7025486 on 9q33 was found to associate with abdominal aortic aneurysms; Rs7025486 is located within DAB2IP PMID: 20622881
47. Data show that loss of DAB2IP expression repressed E-cadherin and increased vimentin in both normal prostate epithelial and prostate carcinoma cells as well as in clinical prostate-cancer specimens. PMID: 20080667
48. functions as a signaling scaffold that coordinately regulates Ras and NF-kappaB through distinct domains to promote prostate cancer growth and metastasis PMID: 20154697
49. Data show that DAB2IP is a potent growth inhibitor by inducing G(0)/G(1) cell cycle arrest and is proapoptotic in response to stress, and that DAB2IP can suppress the PI3K-Akt pathway and enhance ASK1 activation leading to cell apoptosis. PMID: 19903888
50. Epigenetic regulation of this novel tumor suppressor gene in prostate cancer cell lines. PMID: 12446720
顯示更多

收起更多
相關疾?。?/div>
A chromosomal aberration involving DAB2IP is found in a patient with acute myeloid leukemia (AML). Translocation t(9;11)(q34;q23) with KMT2A/MLL1. May give rise to a KMT2A/MLL1-DAB2IP fusion protein lacking the PH domain (PubMed:14978793).
亞細胞定位：

Cytoplasm. Cell membrane; Peripheral membrane protein. Membrane. Cell projection, dendrite.
組織特異性：

Expressed in endothelial and vascular smooth muscle cells (VSMCs). Expressed in prostate epithelial but poorly in prostate cancer cells. Poorly expressed in medulloblastoma cells compared to cerebellar precursor proliferating progenitor cells (at protein
數據庫鏈接：

HGNC: 17294

OMIM: 609205

KEGG: hsa:153090

STRING: 9606.ENSP00000259371

UniGene: Hs.522378

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human